002349

6.781.02%

JINGHUA PHARM: Ritonavir has received approval for the listing application of chemical raw materials

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, JINGHUA PHARM (002349.SZ) announced that its subsidiary, JINGHUA PHARM Group Nantong Co., Ltd. (hereinafter referred to as "Nantong Company"), has received the approval notice for the listing application of Ritonavir raw materials issued by the National Medical Products Administration.

Ritonavir raw materials are downstream raw material extensions of the Ritonavir pharmaceutical intermediates produced by Nantong Company. It is an antiviral drug primarily used for the treatment of AIDS. During the COVID-19 pandemic, Ritonavir was also one of the main drugs used for treating COVID-19.

The approval of Ritonavir's listing application indicates that this raw material has met the relevant technical standards for raw material review in the country. After complying with the requirements of Good Manufacturing Practice (GMP), it can be produced and sold in the domestic market, which is beneficial for expanding the product's sales in the domestic market and enhancing the company's market competitiveness in the field of chemical raw materials

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.